(Boursier.com) — Lysogen , a Phase 3 biopharmaceutical company based on a gene therapy technology platform targeting diseases of the central nervous system (CNS), today announces the appointment of Côme de La Tour du Pin, currently VP Finance/CFO ad interim, as Chief Financial Officer. He will replace Stéphane Durant des Aulnois who has decided to leave the company to pursue other opportunities.
Mr. de La Tour du Pin joined the company in 2020 as Vice-President Finance before taking on the role of interim Chief Financial Officer in November 2022, and has been involved in fundraising, investor relations and of FP&A. Before joining Lysogene, he acquired solid experience in investor relations at Ipsen and within the Group. Casino. He had previously developed solid skills in investment banking at BNP Paribas and in audit at PwC. Côme graduated from EM Lyon Business School.
©2023 Boursier.com